27
November
2012
|
00:00
Europe/London

UK first for new eye treatment trial

9135_large-2.jpg

A team of Manchester eye specialists has treated the first two patients in a new trial of radiotherapy for the eye disease wet age-related macular degeneration (AMD).

The radiotherapy is delivered by a non-invasive robotic device called IRay® Radiotherapy System which uses low-level radiation, similar to a dental x-ray. Patients treated with the IRay device sit at the machine with their chin on a chin rest. A contact lens is placed on the surface of their eye, and a robot tracks any eye movement via the lens and maintains stability. This allows a controlled dose of radiation to be precisely delivered into the eye on the macula.

The team, led by Mr Tariq Aslam, Consultant Ophthalmologist at Manchester Royal Eye Hospital and Honorary Senior Lecturer at The University of Manchester, conducted an initial clinical trial of IRay in 2011. This trial, called INTREPID, combined radiation therapy with the standard AMD treatment of injections into the eye. The number of injections needed within the treatment group was reduced by 32%, compared to people receiving the standard treatment of a monthly injection into the eye. Certain patients achieved an even higher reduction in injections of up to 50%. 

The Manchester team then worked with the developer of IRay, US-based company Oraya Therapeutics, to make the device even easier to use and to further reduce treatment times for patients and clinical staff. They are now running a clinical trial over the next few months with 10 patients using the enhanced IRay workflow alongside injections.

Patients only need one session of IRay treatment, which potentially can reduce or even remove the need for the regular injections. 

AMD affects thousands of people and is the leading cause of blindness in the UK for people over 65 years of age. Wet AMD is an aggressive form of the disease, affecting 250,000 people in this country, and if left untreated can quickly lead to loss of central vision.

“Treatments such as this under clinical trial conditions represent a significant logistical challenge and Iain McLean, our research manager, and Ekaterina Varimezova-Georgieva, our research co-ordinator, were instrumental to achieving the treatments,” said Mr Aslam.

“This novel therapy has to be co-ordinated with the timing of the patients’ standard treatment and the availability of Oraya’s specialist engineers, who come over from the US to provide technical support. Both Manchester patients were delighted to have been given this novel therapy, which showed significant improvements to standard AMD care in earlier randomised studies.”

Mrs Stella Chandler from North Manchester is one of the first two patients treated with IRay in this new trial. She said: “I joined the trial as I was driven by optimism about the potential benefits of the treatment in my own case, and also because this research could help other people. Having regular injections into one or both eyes is a traumatic process, so anything that reduces the frequency of the injections will be a positive result.”

Local funding support helped the trial to take place in Manchester. Debbie Vinsun, Greater Manchester Comprehensive Local Research Network (GM CLRN) senior manager, said: "Congratulations to Tariq and the ophthalmology team at the Royal Eye Hospital. They have used National Institute for Health Research GM CLRN funding to support staff with different skills, such as a photographer, nurses and a co-ordinator, to ensure that patients in Greater Manchester are getting access to treatments which are not only cutting edge but show promising improvements to the current treatments."

Mr Aslam added: "IRay is an exciting new technology that targets one of the most common causes of blindness in the UK. If the initial results are borne out in this further trial, then a majority of patients will have something to look forward to - an easily administered, one-off treatment that maintains or improves vision, and fewer injections into their eye."

Ends

Notes for editors

The INTREPID study is the first sham-controlled double-masked trial to evaluate the effectiveness and safety of a one-time radiation therapy in conjunction with as-needed anti-VEFG injections for the treatment of wet AMD. The results of the study were presented during the EURETINA Congress in Milan in September 2012. 

The National Institute for Health Research is funded by the Department of Health to improve the health and wealth of the nation through research. Since its establishment in April 2006, the NIHR has transformed research in the NHS. It has increased the volume of applied health research for the benefit of patients and the public, driven faster translation of basic science discoveries into tangible benefits for patients and the economy, and developed and supported the people who conduct and contribute to applied health research. The NIHR plays a key role in the Government’s strategy for economic growth, attracting investment by the life-sciences industries through its world-class infrastructure for health research. Together, the NIHR people, programmes, centres of excellence and systems represent the most integrated health research system in the world. For further information, visit the NIHR website (www.nihr.ac.uk).

Central Manchester University Hospitals NHS Foundation Trust is a leading provider of specialist healthcare services in Manchester, treating more than a million patients every year. Its eight specialist hospitals (Manchester Royal Infirmary, Saint Mary’s Hospital, Royal Manchester Children’s Hospital, Manchester Royal Eye Hospital, University Dental Hospital of Manchester and Trafford Hospitals) are home to hundreds of world class clinicians and academic staff committed to finding patients the best care and treatments. (www.cmft.nhs.uk)

Oraya Therapeutics, Inc. is a privately-held company developing innovative and non-invasive therapies for diseases of the eye. Founded in 2006, Oraya is funded by Essex Woodlands Health Ventures, Synergy Life Science Partners, Scale Venture Partners and Domain Associates.

The University of Manchester, a member of the Russell Group, is one of the largest and most popular universities in the UK. It has 20 academic schools and hundreds of specialist research groups undertaking pioneering multi-disciplinary teaching and research of worldwide significance. According to the results of the 2008 Research Assessment Exercise, The University of Manchester is one of the country’s major research institutions, rated third in the UK in terms of ‘research power’. The University had an annual income of £809 million in 2010/11. (www.manchester.ac.uk)

For further information please contact:

Lucy Prosser
Web Communications Officer
Manchester Biomedical Research Centre

Tel: 0161 701 0260
Mob: 0782 514 2219
Email: lucy.prosser@cmft.nhs.uk

Or Aeron Haworth
Media Relations
Faculty of Medical and Human Sciences
The University of Manchester

Tel: 0161 275 8383
Mob: 07717 881563
Email: aeron.haworth@manchester.ac.uk